<DOC>
	<DOCNO>NCT00000714</DOCNO>
	<brief_summary>To determine safety effectiveness investigational drug therapy ( trimetrexate plus leucovorin calcium ( TMTX / LCV ) ) treatment Pneumocystis carinii pneumonia ( PCP ) patient AIDS , HIV positive , high risk HIV infection , suffer severe life-threatening ill effect conventional therapy PCP . AMENDED : 08/01/90 As August 31 , 1989 , 437 patient enrol uncontrolled study trimetrexate PCP:214 TX 301/ACTG 0=039 ( trimetrexate patient intolerant approved therapy ) 223 NS 401 ( trimetrexate patient refractory approved therapy ) . The analysis overall response rate , stringently define receive least 14 day trimetrexate alive follow-up 1 month completion therapy , reveal 84/159 intolerant patient 48/160 refractory patient respond , rate 53 percent 30 percent , respectively . These response rate include individual receive least one dose trimetrexate . Of 111 patient ventilator-dependent study entry , 18 complete course therapy alive month later , response rate 16 percent . All ventilate patient die . The common severe ( grade 3 4 ) toxicity : transaminase elevation ( &gt; 5 x normal ) 94 patient , anemia ( &lt; 7.9 g/dl ) 109 , neutropenia ( &lt; 750 cells/mm3 ) 58 , fever ( &gt; 40 C ) 37 , thrombocytopenia ( &lt; 50000 platelets/mm3 ) 27 . Toxicity require discontinuation therapy approximately 5 percent patient . Original design : The drug usually use treat PCP AIDS patient , trimethoprim / sulfamethoxazole pentamidine , discontinue many patient severe side effect . Currently proven alternative drug . TMTX choose trial find active PCP organism laboratory test . Also TMTX , combination LCV , high response rate cause severe toxicity preliminary trial .</brief_summary>
	<brief_title>An Open , Prospective , Multicenter Study Trimetrexate With Leucovorin Rescue AIDS Patients With Pneumocystis Carinii Pneumonia ( PCP ) Serious Intolerance Approved Therapies</brief_title>
	<detailed_description>AMENDED : 08/01/90 As August 31 , 1989 , 437 patient enrol uncontrolled study trimetrexate PCP:214 TX 301/ACTG 0=039 ( trimetrexate patient intolerant approved therapy ) 223 NS 401 ( trimetrexate patient refractory approved therapy ) . The analysis overall response rate , stringently define receive least 14 day trimetrexate alive follow-up 1 month completion therapy , reveal 84/159 intolerant patient 48/160 refractory patient respond , rate 53 percent 30 percent , respectively . These response rate include individual receive least one dose trimetrexate . Of 111 patient ventilator-dependent study entry , 18 complete course therapy alive month later , response rate 16 percent . All ventilate patient die . The common severe ( grade 3 4 ) toxicity : transaminase elevation ( &gt; 5 x normal ) 94 patient , anemia ( &lt; 7.9 g/dl ) 109 , neutropenia ( &lt; 750 cells/mm3 ) 58 , fever ( &gt; 40 C ) 37 , thrombocytopenia ( &lt; 50000 platelets/mm3 ) 27 . Toxicity require discontinuation therapy approximately 5 percent patient . Original design : The drug usually use treat PCP AIDS patient , trimethoprim / sulfamethoxazole pentamidine , discontinue many patient severe side effect . Currently proven alternative drug . TMTX choose trial find active PCP organism laboratory test . Also TMTX , combination LCV , high response rate cause severe toxicity preliminary trial . Patients enter study give TMTX 21 day LCV 24 day . Doses determine body size . Both drug give intravenous infusion , LCV may give orally first 10 day . It essential ensure patient receive every dose LCV LCV therapy continue full 3 day TMTX therapy complete discontinue . Doses adjust side effect , low white blood cell count , severe . During 21-day trial , zidovudine ( AZT ) may use , possible increase bone marrow toxicity . AZT may resume soon administration TMTX LCV complete .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Noninvestigational therapy need . Maintenance therapy investigational triazoles itraconazole SCH 39304 . Highdose corticosteroid ( exceed physiologic replacement dos ) include oral prednisone 40 mg bid 5 day , 40 mg daily 5 day 20 mg daily remainder PCP therapy . Same dose methylprednisolone . Concurrent Treatment : Allowed : Any ventilatory support , antihypertensive agent , invasive monitoring , necessary medical intervention , accord his/her medical status , personal wish , judgment his/her physician . Patients must : HIV seropositivity . Diagnosis Pneumocystis carinii pneumonia ( PCP ) . Serious intolerance trimethoprim / sulfamethoxazole ( TMP / SMX ) therapy define follow : Platelets &lt; 50000 platelets/mm3 . Neutrophil count ( polys plus band ) = &lt; 500 cells/mm3 least two occasion = &gt; 12 hour apart . Mucocutaneous reaction blister rash , mucosal involvement , generalize maculopapular eruption , intolerable pruritus . Hepatitis demonstrate transaminase elevation &gt; 5 time upper limit normal , = &gt; 300 IU baseline abnormal . Drug fever daily temperature = &gt; 103 degree F begin 5th day treatment persist least 3 day responsive antipyretic therapy , discernible cause . Any severe lifethreatening adverse reaction TMP / SMX , investigator 's opinion , make continued recurrent treatment TMP / SMX inadvisable determine casebycase basis . Serious intolerance pentamidine therapy define follow : Platelets &lt; 50000 platelets/mm3 . Neutrophil count ( polys plus band ) = &lt; 500 cells/mm3 least two occasion = &gt; 12 hour apart . Serum creatinine &gt; 3.0 mg/dl . Systolic blood pressure &lt; 90 mm require supportive therapy . Symptomatic hypoglycemia blood glucose &lt; 40 , hyperglycemia require therapy . Pancreatitis laboratory confirmation ( abnormal amylase and/or lipase ) . Any severe lifethreatening adverse reaction pentamidine , , investigator 's opinion , make continued recurrent treatment pentamidine inadvisable determined casebycase basis . Informed consent patient legal guardian . Prior Medication : Required : Trimethoprim / sulfamethoxazole pentamidine therapy . Prior Medication : Allowed : Myelosuppressive nephrotoxic agent include zidovudine . History highrisk behavior HIV infection homosexual bisexual men , intravenous drug abuser , recipient HIVinfected blood product , sexual partner person group may admit without proof HIV infection . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : History Type I hypersensitivity ( i.e. , urticaria , angioedema , anaphylaxis ) , exfoliative dermatitis , lifethreatening reaction due trimetrexate . Patients less severe adverse reaction may enrol , opinion investigator , adverse effect prohibit rechallenge drug . Concurrent Medication : Excluded : Myelosuppressive nephrotoxic agent include zidovudine ganciclovir . Investigational therapy . Patients follow excluded : History Type I hypersensitivity ( i.e. , urticaria , angioedema , anaphylaxis ) , exfoliative dermatitis , lifethreatening reaction due trimetrexate . Patients less severe adverse reaction may enrol , opinion investigator , adverse effect prohibit rechallenge drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Trimetrexate</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiprotozoal Agents</keyword>
</DOC>